WallStSmart

Merck & Company Inc (MRK)vsPulsenmore Ltd. Ordinary Shares (PLSM)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

MRK leads profitability with a 4.8% profit margin vs -65.9%. PLSM earns a higher WallStSmart Score of 39/100 (F).

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

PLSM

Hold

39

out of 100

Grade: F

Growth: 8.0Profit: 2.5Value: 5.0Quality: 5.0
Piotroski: 4/9Altman Z: 0.87
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-78.2%)

Margin of Safety

-78.2%

Fair Value

$83.04

Current Price

$148.03

$64.98 premium

UndervaluedFair: $83.04Overvalued

Intrinsic value data unavailable for PLSM.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$365.34B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

PLSM1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
52.0%10/10

Revenue surging 52.0% year-over-year

Areas to Watch

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.7x4/10

Trading at 8.7x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

PLSM4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$15.74M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Return on EquityProfitability
-31.0%2/10

ROE of -31.0% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bull Case : PLSM

The strongest argument for PLSM centers on Revenue Growth. Revenue growth of 52.0% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 120.4x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Bear Case : PLSM

The primary concerns for PLSM are EPS Growth, Market Cap, Operating Margin.

Key Dynamics to Monitor

MRK profiles as a value stock while PLSM is a hypergrowth play — different risk/reward profiles.

PLSM carries more volatility with a beta of 0.40 — expect wider price swings.

PLSM is growing revenue faster at 52.0% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

PLSM scores higher overall (39/100 vs 36/100) and 52.0% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Pulsenmore Ltd. Ordinary Shares

HEALTHCARE · MEDICAL DEVICES · USA

Pulsenmore Ltd. engages in the provision of self-scan ultrasound devices for remote clinical diagnosis and screening in Israel and Europe. The company is headquartered in Omer, Israel.

Want to dig deeper into these stocks?